Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Consistent Results after Dosing with EP-104GI
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis , Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
Metalsource Mining Strengthens Strategic Communications and Market Awareness as Exploration Advances at America's First Silver Mine
Sun Summit Commences Fully Funded 10,000 Meter Drill Program at the JD Project, Toodoggone Mining District, B.C.
